DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing
Scientific Reports · 2024
DOI: 10.1038/s41598-024-66075-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Vladimir Laletin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Cancérologie de Marseille, CRCM, Immunity and Cancer Team, Institut Paoli-Calmettes, Inserm, CNRS, Aix Marseille University, M…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, RNA-Binding Proteins, Signal Transduction, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Targeting intracellular inhibiting proteins has been revealed to be a promising strategy to improve CD8 + T cell anti-tumor efficacy. Here, we are focusing on intracellular inhibiting proteins specific to TCR signaling: DOK1 and DOK2 expressed in T cells. We hypothesized that depletion of intracellular inhibition checkpoint DOK1 and DOK2 could improve CD8 + T-cell based cancer therapies. To evaluate the role of DOK1 and DOK2 depletion in physiology and effector function of CD8 + T lymphocytes and in cancer progression, we established a transgenic T cell receptor mouse model specific to melanoma antigen hgp100 (pmel-1 TCR Tg) in WT and Dok1 / Dok2 DKO (double KO) mice. We showed that both DOK1 and DOK2 depletion in CD8 + T cells after an in vitro pre-stimulation induced a higher percentage of effector memory T cells as well as an up regulation of TCR signaling cascade- induced by CD3 mAbs, including the increased levels of pAKT and pERK, two major phosphoproteins involved in T cell functions. Interestingly, this improved TCR signaling was not observed in naïve CD8 + T cells. Despite this enhanced TCR signaling essentially shown upon stimulation via CD3 mAbs, pre-stimulated Dok1 / Dok2 DKO CD8 + T cells did not show any increase in their activation or cytotoxic capacities against melanoma cell line expressing hgp100 in vitro. Altogether we demonstrate here a novel aspect of the negative regulation by DOK1 and DOK2 proteins in CD8 + T cells. Indeed, our results allow us to conclude that DOK1 and DOK2 have an inhibitory role following long term T cell stimulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de Recherche en Cancérologie de Marseille, CRCM, Immunity and Cancer Team, Institut Paoli-Calmettes, Inserm, CNRS, Aix Marseille University, Marseille, France.
- Centre de Recherche en Cancérologie de Marseille, CRCM, TrGET Pre-Clinical Assay Platform, Institut Paoli-Calmettes, Inserm, CNRS, Aix Marseille University, Marseille, France.
- Division of Genetics, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
- Centre de Recherche en Cancérologie de Marseille, CRCM, Immunity and Cancer Team, Institut Paoli-Calmettes, Inserm, CNRS, Aix Marseille University, Marseille, France. jacques.nunes@inserm.fr.
ORCID-Profile: Geoffrey Guittard, Jacques A Nunès
Zitieren
APA
Laletin, V., Bernard, P. L., Montersino, C., Yamanashi, Y., Olive, D., Castellano, R., Guittard, G., & Nunès, J. A. (2024). DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing. Scientific Reports. https://doi.org/10.1038/s41598-024-66075-0
Vancouver
Laletin V, Bernard PL, Montersino C, Yamanashi Y, Olive D, Castellano R, et al. DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing. Scientific Reports. 2024. doi:10.1038/s41598-024-66075-0
BibTeX
@article{Laletin2024,
author = {Laletin, Vladimir and Bernard, Pierre-Louis and Montersino, Camille and Yamanashi, Yuji and Olive, Daniel and Castellano, Rémy and Guittard, Geoffrey and Nunès, Jacques A},
title = {DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-66075-0}
}
EUVIMED